mRNA Vaccine Platform for CMV Using Lipid Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective and safe solution for preventing congenital cytomegalovirus (CMV) infection and CMV infection in immunosuppressed individuals post-transplantation, with existing vaccines and treatments having limitations in efficacy and stability.
Innovation Solution
Development of an mRNA-based vaccine platform using specific molar ratios of mRNA encoding CMV proteins (gH, gL, UL128, UL130, UL131A, and gB) formulated in lipid nanoparticles, which induces targeted immune responses and maintains stability for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine methods are used, then vaccine development can proceed with established techniques, but the vaccine lacks efficacy and stability in preventing congenital CMV infection
Solution Approach 1:
The patent employs a composite mRNA-lipid nanoparticle formulation where synthetic mRNA encoding CMV antigens is encapsulated within lipid nanoparticles. This composite structure protects the mRNA from degradation, facilitates cellular uptake, and enables stable storage, thereby achieving both high efficacy and improved stability while maintaining manageable formulation complexity through standardized lipid nanoparticle technology
Solution Approach 2:
The patent utilizes specific molar ratios of different mRNA components (gH:gL:UL128:UL130:UL131A:gB = 2:1:1:1:1:2) to optimize immune response. By precisely controlling the parametric composition of mRNA encodings for different CMV glycoproteins, the vaccine achieves enhanced immunogenicity and stability, demonstrating how parameter optimization can improve vaccine performance without excessive complexity
2Stability of the object's composition
If mRNA components are present in equal masses, then manufacturing is simplified, but stability and potency are reduced
Solution Approach 1:
The patent specifies precise molar ratios (2:1:1:1:1:2) for mRNA components encoding different CMV antigens instead of using equal masses. This parameter change optimizes the relative amounts of each antigen presented to the immune system, enhancing both stability and potency. The standardized ratio approach, while requiring precise formulation, enables reproducible manufacturing with controlled parameters
3Reliability
If the vaccine induces strong immune responses, then protection against CMV is improved, but the vaccine may cause adverse reactions
Solution Approach 1:
The patent extracts only the essential immunogenic components (specific CMV glycoprotein antigens: gH, gL, UL128, UL130, UL131A, and gB) and presents them through mRNA encoding without using whole virus or live attenuated forms. This extraction of specific antigens induces targeted immune responses against CMV while eliminating harmful factors associated with whole-virus vaccines, such as uncontrolled replication and non-specific immune activation that could cause adverse reactions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mRNA-based vaccine platform effectively induces antigen-specific immune responses, including neutralizing antibodies, and demonstrates increased stability and potency, addressing the unmet medical need for CMV prevention in both congenital and post-transplantation settings.
Implementation Method 1
target viral proteins or antigens can be produced in vivo by delivery and cellular uptake of the corresponding synthetic viral mRNA from delivery of an immunogenic composition formulated in a lipid nanoparticle
Implementation Method 2
The mRNA then undergoes intracellular ribosomal translation to endogenously express the viral protein antigens encoded by the vaccine immunogenic composition
Data Source
AI summary
Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.